Junqi Niu

Xi'an Jiaotong University — China

Medicine · Health Sciences

51h-index10.1kcitations425works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(208), Hepatitis B Virus Studies(203), Liver Disease Diagnosis and Treatment(170), Hepatocellular Carcinoma Treatment and Prognosis(23), Immune Cell Function and Interaction(22)

Publications425 total

Molecular dynamics study of the desorption mechanism for shale oil in supercritical water within reservoir nano-slits
Fuel·2026
Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study
MedComm·2025Open Access
Comprehensive analysis of membrane thickness and reinforcement ratio effects on the performance and durability of polymer electrolyte membranes
Journal of Membrane Science·2025
<em>Lactobacillus acidophilus</em> Attenuates Ulcerative Colitis by Strengthening Intestinal Barrier Integrity and Modulating Microbiota-Immune Crosstalk
Food Science and Human Wellness·2025Open Access
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses
Journal of Hepatology·2025· 2 cited
Rational design of MAO-B-activated fluorescent probe for activity evaluation and its biomedical applications
Free Radical Biology and Medicine·2025
Response to letter to the editor “Methodological considerations for recombinant human serum albumin clinical translation”
Hepatology International·2025
Aldehyde Dehydrogenase 2 Deficiency Impairs Liver Progenitor Cell Proliferation in Alcohol-Fed Mice
American Journal Of Pathology·2025· 1 cited
Advance in molecular mechanisms underlying diabetes related to viral hepatitis infection
Frontiers in Cellular and Infection Microbiology·2025· 1 citedOpen Access
A Kinetic Study on the Accumulation of No.0 Fuel Oil and Pinghu Crude Oil Water-Accommodated Fraction in Exopalaemon carinicauda
Fishes·2025Open Access
Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study
EClinicalMedicine·2025· 1 citedOpen Access
Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Data from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Table S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Table S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Figure S2 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
2025Open Access
page 1 of 22Next →

Frequent Co-authors

Jidong Jia(8), Xiaomei Wang(7), Jian Sun(7), Jinlin Hou(7), Yanhang Gao(7), Hong Tang(7), Deming Tan(6), Mobin Wan(6), Jifang Sheng(6), Jin Zhong(6), Xiaoguang Dou(5), Rong Fan(5), Hong Ren(5), Qin Ning(5), Xiumei Chi(5), Maorong Wang(5), Yu Pan(5), Jia Shang(4), Qing Xie(4), Ruihong Wu(4)